(Q35186637)

7 August 2017

1 reference

title

Acyclovir: a decade later (English)

1 reference

7 August 2017

Acyclovir: A Decade Later (English)

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

26 November 2023

1 reference

Gnann JW Jr

2

1 reference

7 August 2017

R. J. Whitley

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1288525

9 September 2022

J. W. Gnann

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1288525

9 September 2022

language of work or name

English

0 references

publication date

1 September 1992

1 reference

7 August 2017

10 September 1992

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1288525

full work available at URL

9 September 2022

http://www.nejm.org/doi/pdf/10.1056/NEJM199209103271108

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

The New England Journal of Medicine

26 November 2023

published in

1 reference

7 August 2017

327

1 reference

7 August 2017

11

1 reference

7 August 2017

782-789

1 reference

Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine

7 August 2017

1

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

9-(2-Hydroxyethoxymethyl)guanine activity against viruses of the herpes group

26 November 2023

2

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Inhibition of herpes simplex virus-induced DNA polymerase activity and viral DNA replication by 9-(2-hydroxyethoxymethyl)guanine and its triphosphate

26 November 2023

6

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

The activity in vitro against herpes virus of 9-(2-hydroxyethoxymethyl)guanine (acycloguanosine), a new antiviral agent

26 November 2023

7

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Growth Inhibition by Acycloguanosine of Herpesviruses Isolated from Human Infections

26 November 2023

8

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

In vitro susceptibility of varicella-zoster virus to acyclovir

26 November 2023

9

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Acyclovir inhibition of Epstein-Barr virus replication

26 November 2023

10

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Pharmacokinetics of acyclovir after intravenous and oral administration.

26 November 2023

11

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Acyclovir. Pharmacology and clinical experience

26 November 2023

12

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Pharmacokinetics of acyclovir in humans following intravenous administration. A model for the development of parenteral antivirals

26 November 2023

13

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Scandinavian journal of infectious diseases. Supplementum

26 November 2023

14

47

33

Brigden

1985

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

A Trial of Topical Acyclovir in Genital Herpes Simplex Virus Infections

26 November 2023

15

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Effect of low dose acyclovir (5 mg/kg) on virus shedding, interferon and humoral immunity in herpes zoster

26 November 2023

16

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Intravenous Acyclovir for the Treatment of Primary Genital Herpes

26 November 2023

17

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Intravenous acyclovir therapy of first episodes of genital herpes: a multicenter double-blind, placebo-controlled trial

26 November 2023

18

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. A randomized double-blind controlled trial in normal subjects

26 November 2023

19

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Topically administered acyclovir in the treatment of recurrent herpes simplex genitalis: a controlled trial

26 November 2023

21

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

A collaborative study of patient-initiated treatment of recurrent genital herpes with topical acyclovir or placebo

26 November 2023

22

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial

26 November 2023

23

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes

26 November 2023

24

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

A Double-Blind Study of Oral Acyclovir for Suppression of Recurrences of Genital Herpes Simplex Virus Infection

26 November 2023

25

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Suppression of frequently recurring genital herpes. A placebo-controlled double-blind trial of oral acyclovir

26 November 2023

27

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Acyclovir suppression of frequently recurring genital herpes. Efficacy and diminishing need during successive years of treatment

26 November 2023

29

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Recurrent genital herpes and suppressive oral acyclovir therapy. Relation between clinical outcome and in-vitro drug sensitivity.

26 November 2023

30

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Effect of oral acyclovir treatment on symptomatic and asymptomatic virus shedding in recurrent genital herpes.

26 November 2023

31

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Successful treatment of herpes labialis with topical acyclovir.

26 November 2023

32

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Treatment of herpes simplex labialis with topical acyclovir in polyethylene glycol

26 November 2023

33

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Oral acyclovir and herpes labialis: a randomized, double-blind, placebo-controlled study

26 November 2023

35

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Treatment of recurrent herpes simplex labialis with oral acyclovir

26 November 2023

36

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation: a double-blind trial

26 November 2023

38

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host

26 November 2023

39

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Oral acyclovir therapy for mucocutaneous herpes simplex virus infections in immunocompromised marrow transplant recipients

26 November 2023

40

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Acyclovir prophylaxis of herpes-simplex-virus infections

26 November 2023

41

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Oral Acyclovir for Prevention of Herpes Simplex Virus Reactivation After Marrow Transplantation

26 November 2023

42

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Frequency and significance of acyclovir-resistant herpes simplex virus isolated from marrow transplant patients receiving multiple courses of treatment with acyclovir

26 November 2023

44

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Vidarabine versus acyclovir therapy in herpes simplex encephalitis.

26 November 2023

45

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Acyclovir versus vidarabine in herpes simplex encephalitis. Randomised multicentre study in consecutive Swedish patients.

26 November 2023

46

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group

26 November 2023

47

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Herpes simplex virus encephalitis in children: analysis of cerebrospinal fluid and progressive neurodevelopmental deterioration

26 November 2023

48

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

A comparison between acyclovir and trifluorothymidine ophthalmic ointment in the treatment of epithelial dendritic keratitis. A double blind, randomized parallel group trial

26 November 2023

49

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Acyclovir treatment of varicella in otherwise healthy children

26 November 2023

50

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

A controlled trial of acyclovir for chickenpox in normal children

26 November 2023

51

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Acyclovir treatment of varicella in otherwise healthy adolescents. The Collaborative Acyclovir Varicella Study Group

26 November 2023

52

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Treatment of adult chickenpox with oral acyclovir

26 November 2023

53

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Acyclovir therapy of chickenpox in immunosuppressed children--a collaborative study

26 November 2023

55

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Acyclovir prevents dissemination of varicella in immunocompromised children.

26 November 2023

56

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Acyclovir therapy for acute herpes zoster

26 November 2023

57

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Acyclovir in herpes zoster

26 November 2023

58

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Intravenous acyclovir in acute herpes zoster infection

26 November 2023

59

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

A 54-year-old woman with fevers, arthralgias, myalgias, and rash

26 November 2023

60

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Oral acyclovir in the treatment of acute herpes zoster ophthalmicus

26 November 2023

63

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Acyclovir Halts Progression of Herpes Zoster in Immunocompromised Patients

26 November 2023

64

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Treatment of varicella-zoster virus infection in severely immunocompromised patients. A randomized comparison of acyclovir and vidarabine

26 November 2023

65

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Lack of effect of acyclovir on postherpetic neuralgia

26 November 2023

66

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Early vidarabine therapy to control the complications of herpes zoster in immunosuppressed patients

26 November 2023

67

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Disseminated herpes zoster in the immunocompromised host: a comparative trial of acyclovir and vidarabine. The NIAID Collaborative Antiviral Study Group

26 November 2023

68

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Treatment of Cytomegaloviral Pneumonia with High-Dose Acyclovir and Human Leukocyte Interferon

26 November 2023

69

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation

26 November 2023

70

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

A Randomized, Placebo-Controlled Trial of Oral Acyclovir for the Prevention of Cytomegalovirus Disease in Recipients of Renal Allografts

26 November 2023

71

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis.

26 November 2023

72

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Chronic Epstein-Barr virus infection associated with fever and interstitial pneumonitis. Clinical and serologic features and response to antiviral chemotherapy

26 November 2023

73

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Epstein-Barr Virus Lymphoproliferative Disease Associated with Acquired Immunodeficiency

26 November 2023

75

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Acyclovir treatment of the chronic fatigue syndrome. Lack of efficacy in a placebo-controlled trial

26 November 2023

76

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

B virus (Herpesvirus simiae) infection in humans: epidemiologic investigation of a cluster

26 November 2023

77

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Controlled clinical trial of acyclovir in chronic hepatitis B virus infection

26 November 2023

78

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Phase I study of low-dose zidovudine and acyclovir in asymptomatic human immunodeficiency virus seropositive individuals

26 November 2023

79

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Isolation and characterisation of resistant Herpes simplex virus after acyclovir therapy

26 November 2023

80

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir

26 November 2023

81

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Progressive esophagitis from acyclovir-resistant herpes simplex. Clinical roles for DNA polymerase mutants and viral heterogeneity?

26 November 2023

82

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Frequency and significance of acyclovir-resistant herpes simplex virus isolated from marrow transplant patients receiving multiple courses of treatment with acyclovir

26 November 2023

83

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome.

26 November 2023

84

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group

26 November 2023

85

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial

26 November 2023

86

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Acyclovir-resistant herpes simplex virus causing pneumonia after marrow transplantation

26 November 2023

87

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Herpes simplex virus type 2 meningoencephalitis resistant to acyclovir in a patient with AIDS.

26 November 2023

88

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Herpes simplex virus resistant to acyclovir. A study in a tertiary care center

26 November 2023

89

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Acyclovir-resistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome (AIDS).

26 November 2023

92

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Foscarnet Therapy in Five Patients with AIDS and Acyclovir-resistant Varicella-Zoster Virus Infection

26 November 2023

93

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Acyclovir-induced renal failure: course and risk factors

26 November 2023

95

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Renal function after acyclovir intravenous injection

26 November 2023

96

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Neurologic Symptoms Associated with Parenteral Acyclovir Treatment After Marrow Transplantation

26 November 2023

97

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Severe but reversible neurotoxicity from acyclovir

26 November 2023

98

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

Pharmacokinetics of acyclovir in the term human pregnancy and neonate

26 November 2023

100

1 reference

https://api.crossref.org/works/10.1056/NEJM199209103271108

26 November 2023

Identifiers

1 reference

7 August 2017

1 reference